Report of the UK Cystic Fibrosis Trust Antibiotic Working Group

More documents

Recommendations

Info

Cefotaxime intravenouslyAge Dose Frequency1 month–18 years 50 mg/kg (max 12 g in 24hours) 6–8 hourlyAdult 2 g (max 12 g in 24 hours) 8 hourlyPreparationsAdministration500 mg, 1 g and 2 g vials.Slow intravenous injection over 3–4 minutes.Side-effects Similar to cefaclor (section 8.4).NotesReduce dose in renal impairment. Less active against S.aureus than cefuroxime.8.6 Treatment <strong>of</strong> atypical infection e.g. Mycoplasma & Non-tuberculousmycobacteria (section 7.8.3)Clarithromycin orally (for Mycobacterium avium complex – MAC)and intravenously (M.abscessus)Age Dose Frequency
Rifampicin (MAC) See section 8.2 for preparation, administration side effects and notes. InMAC infection rifampicin is administered 24 hourly.Age Dose Frequency1–12 years 10 mg/kg 24 hourly>12 years & adult 12 years & adult ≥50kg 600 mg od 24 hourlyEthambutol (MAC)Age Dose FrequencyAll ages 15 mg/kg (max 1.5 g) 24 hourlyPreparationsAdministration500 mg, 1 g and 2 g vials.Slow intravenous injection over 3–4 minutes.Side-effects Similar to cefaclor (section 8.4).NotesReduce dose in renal impairment. Less active against S.aureus than cefuroxime.Cefoxitin (M.abscessus)Age Dose FrequencyChild
Page 3 and 4:
4. ORAL ANTIBIOTICS IN CYSTIC FIBRO
Page 5 and 6:
7. OTHER INFECTIONS7.1 Management o
Page 7 and 8:
GRADING SCHEME FOR LEVELS OF EVIDEN
Page 9 and 10:
SUMMARY•All young children with c
Page 11:
In 1989 the Copenhagen centre recom
Page 15 and 16:
These bacteria can be harmless comm
Page 17 and 18:
2.7 Clinical relevance of in vitro
Page 19 and 20:
17. Macia MD, Blanquer D, Togores B
Page 21 and 22:
3.1 Introduction3. IDENTIFICATION O
Page 23 and 24:
Table 2: Laboratory techniques and
Page 25 and 26:
20. Hoppe JE, Theurer MU, Stern M.
Page 27 and 28:
4.2.4 Recommendations for treatment
Page 29 and 30:
4.5 Use of oral antibiotics at time
Page 31 and 32:
groups in terms of the chronic use
Page 33 and 34:
5.1 Introduction5. NEBULISED ANTIBI
Page 36 and 37: 5.5 Nebulised antibiotics to preven
Page 38 and 39: 5.10.2 Recommendations for administ
Page 40 and 41: • If a facemask is used the face
Page 42 and 43: 5.16 Nebuliser/compressor systems f
Page 44 and 45: 19. Ratjen F, Walter H, Haug M, Mei
Page 46 and 47: 69. Pitchford KC, Corey M, Highsmit
Page 48 and 49: outcome between active and placebo
Page 50 and 51: Drug Route Age/weight DoseFrequency
Page 52 and 53: much sooner. A minimum of 10-14 day
Page 54 and 55: 6.8 References1. Armstrong DS, Grim
Page 56 and 57: 7. OTHER INFECTIONS7.1 Management o
Page 58 and 59: 7.2 Respiratory infection with meti
Page 60 and 61: Table 7.2 Published data on eradica
Page 62 and 63: 7.4.2 Recommendations• Given the
Page 64 and 65: although not all authors have found
Page 66 and 67: Table 7.3 Drugs for treatment of My
Page 68 and 69: 7.9.2 Diagnosis of ABPAThe Cystic F
Page 70 and 71: • It is important to assess the c
Page 72 and 73: 12. Blackburn L, Brownlee K, Conway
Page 74 and 75: 57. Ballestero S, Virseda I, Escoba
Page 76 and 77: 107. Deerojanawong J, Sawyer SM, Fi
Page 78 and 79: 155. Stevens DA, Moss RB, Kurup VP,
Page 80 and 81: 8. PHARMACOPOEIAOriginally based on
Page 82 and 83: 8.3 Treatment of more severe exacer
Page 84 and 85: Co-amoxiclav orallyAge Dose Frequen
Page 88 and 89: 8.7 Treatment of Pseudomonas aerugi
Page 90 and 91: 8.8.3 Other ß-lactam antibioticsTh
Page 92 and 93: Amikacin intravenouslyAge Dose Freq
Page 94 and 95: 8.10 Chronic oral anti-pseudomonal
Page 96 and 97: TemocillinAge Dose Frequency>12year
Page 98 and 99: Liposomal Amphotericin (“Ambisome
Page 100 and 101: 9. ANTIBIOTIC-RELATED ALLERGIES AND
Page 102: I N F O R M A T I O NCystic Fibrosi
show all

Report of the UK Cystic Fibrosis Trust Antibiotic Working Group

Create successful ePaper yourself

Delete template?

Save as template?